R-Phenylpiracetam

Selective Dopamine Transporter (DAT) Inhibition#

R-phenylpiracetam is the eutomer of racemic phenylpiracetam (phenotropil) and carries essentially all of the dopaminergic activity of the racemate. In radioligand binding panels covering more than 50 CNS targets, DAT is the only meaningful hit — Ki ≈ 14.8 μM at the rat striatal transporter, with an IC50 of roughly 4.82 μM displacing [¹²⁵I]RTI-55 from human recombinant DAT in CHO-K1 cells. No appreciable affinity has been demonstrated at NMDA, GABA-A/B, nicotinic, muscarinic, 5-HT, adrenergic, opioid, sigma, or histaminergic receptors, making R-PhP an unusually "clean" DAT tool compound rather than a broad-spectrum stimulant.

"MRZ-9547 displayed a high selectivity for the dopamine transporter (DAT). Progressive ratio responding was increased by MRZ-9547 to a greater extent than by methylphenidate, modafinil or d-amphetamine." — Sommer S, Danysz W, Russ H, Valastro B, Flik G, Hauber W. International Journal of Neuropsychopharmacology, 2014

Practically, this is what separates R-PhP from amphetamine-class releasers: it inhibits dopamine reuptake without provoking the large monoamine efflux that produces euphoria, anorexia, and pronounced locomotor activation. The subjective effect described by users — "clean drive, no jitter" — maps directly onto this pharmacology.

Effort-Related Behavior and Anti-Fatigue Output#

Moderate DAT blockade produces a sustained, modest elevation of striatal extracellular dopamine. The downstream behavioral signature is a shift in effort allocation: subjects become willing to work harder for the same reward. On progressive-ratio responding — the standard rodent assay for motivation rather than raw locomotion — R-PhP outperforms methylphenidate, modafinil, and d-amphetamine head-to-head (Sommer et al., 2014).

For the lifter using it pre-training, this is the mechanism that matters. The compound does not feel like a stimulant in the caffeine sense; it feels like the cost of effort drops. Heavy compound sets, conditioning finishers, and long cardio blocks read as less aversive without the heart-rate spike or anxious overdrive of high-dose sympathomimetics. The same effort-shift mechanism explains its reputation in Soviet-era sport for cold tolerance and endurance event support.

Neuroinflammation and Cytokine Suppression#

Beyond acute DAT inhibition, R-PhP exerts a downstream anti-inflammatory effect that is increasingly thought to be mediated through dopaminergic signaling on microglia rather than direct COX or iNOS interaction.

"R-phenylpiracetam attenuated LPS-induced hypothermia, suppressed brain TNF-α, IL-1β, and iNOS overexpression, and dose-dependently reduced carrageenan-induced paw oedema and nociception." — Zvejniece L, et al. Inflammopharmacology, 2020

A single 50 mg/kg ip dose blunted the LPS-driven cytokine storm in mouse brain, and a 7-day pretreatment dose-dependently reduced both peripheral oedema and inflammatory-phase nociception in the formalin test. For physique-focused users, this is a secondary benefit rather than a primary use case — but it does mean R-PhP is not adding inflammatory load on top of a heavy training block the way some stimulants effectively do via sympathetic overdrive.

Rapid CNS Penetration#

R-PhP is highly lipophilic for a piracetam analog — the 4-phenyl substitution does most of the work — and crosses the blood-brain barrier rapidly.

"Peak concentrations of R-phenylpiracetam in the brain were reached approximately 15 minutes following both intraperitoneal and peroral administration." — Zvejniece L, et al. Inflammopharmacology, 2020

Brain Cmax at 50 mg/kg was 28 µg/g tissue ip versus 18 µg/g po, implying oral brain exposure on the order of ~65% of parenteral. This is the pharmacokinetic basis for the standard pre-training window: oral administration 30–45 minutes before the session puts peak central concentration roughly at warm-up. Brain ECF half-life sits around 2–3 hours in rodents, and subjective duration in users tracks the racemate's 3–5 hour clinical half-life, with perceptible effect for ~5–6 hours.

Enantiomeric Specificity — Why R, Not the Racemate#

The R- and S-enantiomers of phenylpiracetam are pharmacologically distinct molecules sharing a name. Resolving them is non-trivial, which is part of why pharmacy phenotropil is sold as the racemate.

"Unlike the R-enantiomer, S-phenylpiracetam did not increase locomotor activity, and exhibited a pronounced anti-obesity effect." — Zvejniece L, et al. Pharmacology Biochemistry and Behavior, 2017

The R-form carries the DAT inhibition, the drive, the focus, and the stimulant profile. The S-form is comparatively inert at DAT and instead modulates appetite and body weight without locomotor activation. Running the resolved R-enantiomer rather than the racemate means roughly double the per-mg potency on the cognitive and pre-workout endpoints users actually care about, at the cost of losing the (modest) appetite-suppressing contribution of the S-form on a cut. Sourcing matters here — HPLC chiral purity on the COA is worth checking, because not every vendor labeling product as "R-phenylpiracetam" is shipping the resolved enantiomer rather than relabeled racemate.

Common (most users)#

• Insomnia — the dominant dose-limiting effect. Dosing past noon reliably wrecks sleep architecture. Mitigation: keep all administration within the first 6 hours of waking, and observe a hard 10-hour cutoff before intended sleep.
• Mild headache — a class effect across all racetams, attributed to accelerated acetylcholine turnover. Mitigation: co-administer a choline source (alpha-GPC 300 mg or CDP-choline 250–500 mg) on dosing days.
• Jitteriness or "wired" feeling — most common in tolerance-naïve users who overshoot the first dose. Mitigation: open at 50 mg and titrate; avoid stacking with high-dose caffeine on the same session.
• Mild appetite reduction — modest and dose-dependent, not the strong suppression seen with amphetamine-class stimulants (the anti-obesity effect tracks with the S-enantiomer, not R). Mitigation: front-load calories earlier in the day.

Uncommon (dose-dependent or individual)#

• Tachycardia and elevated blood pressure — modest at 100 mg, more noticeable at 150 mg and when stacked with caffeine/yohimbine. Resting HR and BP are the practical monitoring endpoints; back off the dose or drop ancillary stimulants if resting HR climbs more than 10–15 bpm above baseline.
• Irritability and "tunnel vision" — narrow, task-locked focus that can tip into social abrasiveness at the upper dose tier. Reduce dose by 25 mg.
• Rapid tolerance / tachyphylaxis — marked diminishing returns within 5–7 consecutive dosing days. Not a side effect in the toxicity sense, but the single biggest reason protocols fail. Mitigation: hold to ≤3 dosing days per week, or use strictly event-driven pulses.
• Mood crash / anhedonia on off-days — predictable rebound from repeated DAT inhibition without recovery. Mitigation: longer washouts between pulses; L-tyrosine 1–2 g on dosing days to support dopamine substrate.

"MRZ-9547 displayed a high selectivity for the dopamine transporter (DAT). Progressive ratio responding was increased by MRZ-9547 to a greater extent than by methylphenidate, modafinil or d-amphetamine." — Sommer et al., 2014

The same DAT selectivity that drives the clean focus profile is what produces the rebound when administration is too frequent — the receptor system needs recovery windows.

Rare but serious#

• Hypertensive episodes — mechanistically plausible in subjects with pre-existing uncontrolled hypertension or when stacked with other dopaminergic/adrenergic agents. Warning signs: severe headache, visual changes, chest tightness. Discontinue immediately.
• Tachyarrhythmia — palpitations beyond mild HR elevation, particularly atrial fibrillation in predisposed subjects. Discontinue and obtain cardiology evaluation.
• Acute anxiety or panic — uncommon, but the dopaminergic push can destabilise users with underlying anxiety disorders. Discontinue.
• Psychotic decompensation — rare, restricted to individuals with personal or strong family history of psychotic illness. Any prodromal signs warrant immediate cessation.

Hard contraindications#

• WADA-tested competition — phenylpiracetam (both enantiomers, racemate and resolved) is prohibited in- and out-of-competition as a non-specified stimulant. Drug-tested athletes do not run this compound, full stop. The R-enantiomer triggers the same positive as racemic phenotropil.
• MAOI use — additive monoaminergic load with unpredictable hypertensive potential. Absolute contraindication.
• Concurrent DAT inhibitors — methylphenidate, modafinil, cocaine, high-dose amphetamines. Mechanistically additive at the same transporter; stacking is not advised.
• Uncontrolled hypertension or pre-existing tachyarrhythmia — the dopaminergic and indirect sympathomimetic profile is incompatible with an already strained cardiovascular system.
• History of psychosis — dopaminergic compounds are contraindicated in this population.
• Severe anxiety disorder — the stimulant profile reliably worsens baseline anxiety.

Gender, pregnancy, and PCT#

R-phenylpiracetam is non-hormonal. There is no virilization risk, no HPTA suppression, no aromatization, and no PCT requirement. Standard dosing applies across the subject pool without gender differential.

No human pregnancy or lactation data exist for the resolved R-enantiomer. Given the absence of safety data and the dopaminergic mechanism, the compound is not appropriate for pregnant or nursing subjects.

Long-term safety data in any population are limited — the published literature is dominated by acute and subchronic rodent work plus decades of CIS clinical experience with the racemate. The community-standard pulsed-use pattern (≤3 dosing days/week, cycles ≤4 weeks) keeps cumulative exposure low and largely sidesteps the question.